We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Acknowledging that its inability to meet customer demand for its Cypher drug-eluting stent has been disappointing, Johnson & Johnson said last week that Cypher inventory is expected to start increasing this month, enabling the company to fill existing back-orders.